Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 505

1.

Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade.

Gong Y, Wang L, Yu H, Alpert N, Cohen MD, Prophete C, Horton L, Sisco M, Park SH, Lee HW, Zelikoff J, Chen LC, Hashim D, Suarez-Farinas M, Donovan MJ, Aaronson SA, Galsky M, Zhu J, Taioli E, Oh WK.

Mol Cancer Res. 2019 Aug;17(8):1605-1612. doi: 10.1158/1541-7786.MCR-19-0115. Epub 2019 Jun 20. Erratum in: Mol Cancer Res. 2019 Aug;17(8):1774.

PMID:
31221798
2.

Retraction Notice to: RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress.

Ongusaha PP, Kim HG, Boswell SA, Ridley AJ, Der CJ, Dotto GP, Kim YB, Aaronson SA, Lee SW.

Curr Biol. 2019 Jun 17;29(12):2107. doi: 10.1016/j.cub.2019.05.065. No abstract available.

3.

SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors.

Ahmed TA, Adamopoulos C, Karoulia Z, Wu X, Sachidanandam R, Aaronson SA, Poulikakos PI.

Cell Rep. 2019 Jan 2;26(1):65-78.e5. doi: 10.1016/j.celrep.2018.12.013.

4.

Kinesin-2 and IFT-A act as a complex promoting nuclear localization of β-catenin during Wnt signalling.

Vuong LT, Iomini C, Balmer S, Esposito D, Aaronson SA, Mlodzik M.

Nat Commun. 2018 Dec 13;9(1):5304. doi: 10.1038/s41467-018-07605-z.

5.

Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B.

van der Touw W, Kang K, Luan Y, Ma G, Mai S, Qin L, Bian G, Zhang R, Mungamuri SK, Hu HM, Zhang CC, Aaronson SA, Feldmann M, Yang WC, Chen SH, Pan PY.

J Immunol. 2018 Sep 15;201(6):1727-1734. doi: 10.4049/jimmunol.1701450. Epub 2018 Aug 1.

6.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

7.

Extracellular LDLR repeats modulate Wnt signaling activity by promoting LRP6 receptor endocytosis mediated by the Itch E3 ubiquitin ligase.

Vijayakumar S, Liu G, Wen HC, Abu Y, Chong R, Nastri H, Bornstein GG, Pan ZQ, Aaronson SA.

Genes Cancer. 2017 Jul;8(7-8):613-627. doi: 10.18632/genesandcancer.146.

8.

DDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation.

Kim HG, Hwang SY, Aaronson SA, Mandinova A, Lee SW.

J Biol Chem. 2017 Apr 28;292(17):7162. doi: 10.1074/jbc.A111.236612. No abstract available.

9.

Investigating the Cellular Specificity in Tumors of a Surface-Converting Nanoparticle by Multimodal Imaging.

Fay F, Hansen L, Hectors SJCG, Sanchez-Gaytan BL, Zhao Y, Tang J, Munitz J, Alaarg A, Braza MS, Gianella A, Aaronson SA, Reiner T, Kjems J, Langer R, Hoeben FJM, Janssen HM, Calcagno C, Strijkers GJ, Fayad ZA, Pérez-Medina C, Mulder WJM.

Bioconjug Chem. 2017 May 17;28(5):1413-1421. doi: 10.1021/acs.bioconjchem.7b00086. Epub 2017 May 5.

10.

Modeling intratumor heterogeneity through CRISPR-barcodes.

Guernet A, Aaronson SA, Anouar Y, Grumolato L.

Mol Cell Oncol. 2016 Sep 6;3(6):e1227894. doi: 10.1080/23723556.2016.1227894. eCollection 2016.

11.

Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Muñoz-Fontela C, Mandinova A, Aaronson SA, Lee SW.

Nat Rev Immunol. 2016 Dec;16(12):741-750. doi: 10.1038/nri.2016.99. Epub 2016 Sep 26. Review.

12.

RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress.

Ongusaha PP, Kim HG, Boswell SA, Ridley AJ, Der CJ, Dotto GP, Kim YB, Aaronson SA, Lee SW.

Curr Biol. 2016 Aug 22;26(16):2221-2222. doi: 10.1016/j.cub.2016.07.072. No abstract available.

13.

CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations.

Guernet A, Mungamuri SK, Cartier D, Sachidanandam R, Jayaprakash A, Adriouch S, Vezain M, Charbonnier F, Rohkin G, Coutant S, Yao S, Ainani H, Alexandre D, Tournier I, Boyer O, Aaronson SA, Anouar Y, Grumolato L.

Mol Cell. 2016 Aug 4;63(3):526-38. doi: 10.1016/j.molcel.2016.06.017. Epub 2016 Jul 21.

14.

Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations.

Troilo A, Benson EK, Esposito D, Garibsingh RA, Reddy EP, Mungamuri SK, Aaronson SA.

Oncotarget. 2016 May 17;7(20):28765-82. doi: 10.18632/oncotarget.9117.

15.

USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation.

Mungamuri SK, Qiao RF, Yao S, Manfredi JJ, Gu W, Aaronson SA.

Cell Rep. 2016 Mar 22;14(11):2528-37. doi: 10.1016/j.celrep.2016.02.049. Epub 2016 Mar 10.

16.

Stable heteroplasmy at the single-cell level is facilitated by intercellular exchange of mtDNA.

Jayaprakash AD, Benson EK, Gone S, Liang R, Shim J, Lambertini L, Toloue MM, Wigler M, Aaronson SA, Sachidanandam R.

Nucleic Acids Res. 2015 Feb 27;43(4):2177-87. doi: 10.1093/nar/gkv052. Epub 2015 Feb 4.

17.

Cdo suppresses canonical Wnt signalling via interaction with Lrp6 thereby promoting neuronal differentiation.

Jeong MH, Ho SM, Vuong TA, Jo SB, Liu G, Aaronson SA, Leem YE, Kang JS.

Nat Commun. 2014 Nov 19;5:5455. doi: 10.1038/ncomms6455.

18.

Scaffold hopping approach on the route to selective tankyrase inhibitors.

Liscio P, Carotti A, Asciutti S, Ferri M, Pires MM, Valloscuro S, Ziff J, Clark NR, Macchiarulo A, Aaronson SA, Pellicciari R, Camaioni E.

Eur J Med Chem. 2014 Nov 24;87:611-23. doi: 10.1016/j.ejmech.2014.10.007. Epub 2014 Oct 5.

19.

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.

Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G.

Cell Death Differ. 2015 Jan;22(1):58-73. doi: 10.1038/cdd.2014.137. Epub 2014 Sep 19. Review.

20.

Ash2L enables P53-dependent apoptosis by favoring stable transcription pre-initiation complex formation on its pro-apoptotic target promoters.

Mungamuri SK, Wang S, Manfredi JJ, Gu W, Aaronson SA.

Oncogene. 2015 May 7;34(19):2461-70. doi: 10.1038/onc.2014.198. Epub 2014 Jul 14.

21.

Brachyury: a new player in promoting breast cancer aggressiveness.

Pires MM, Aaronson SA.

J Natl Cancer Inst. 2014 May 9;106(5). pii: dju094. doi: 10.1093/jnci/dju094. No abstract available.

PMID:
24815862
22.

Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors.

Liscio P, Carotti A, Asciutti S, Karlberg T, Bellocchi D, Llacuna L, Macchiarulo A, Aaronson SA, Schüler H, Pellicciari R, Camaioni E.

J Med Chem. 2014 Mar 27;57(6):2807-12. doi: 10.1021/jm401356t. Epub 2014 Feb 24.

23.

Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers.

Mungamuri SK, Murk W, Grumolato L, Bernstein E, Aaronson SA.

Cell Rep. 2013 Oct 31;5(2):302-13. doi: 10.1016/j.celrep.2013.09.009. Epub 2013 Oct 10.

24.

p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes.

Benson EK, Mungamuri SK, Attie O, Kracikova M, Sachidanandam R, Manfredi JJ, Aaronson SA.

Oncogene. 2014 Jul 24;33(30):3959-69. doi: 10.1038/onc.2013.378. Epub 2013 Oct 7.

25.

The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo.

Hamard PJ, Barthelery N, Hogstad B, Mungamuri SK, Tonnessen CA, Carvajal LA, Senturk E, Gillespie V, Aaronson SA, Merad M, Manfredi JJ.

Genes Dev. 2013 Sep 1;27(17):1868-85. doi: 10.1101/gad.224386.113.

26.

β-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factors.

Grumolato L, Liu G, Haremaki T, Mungamuri SK, Mong P, Akiri G, Lopez-Bergami P, Arita A, Anouar Y, Mlodzik M, Ronai ZA, Brody J, Weinstein DC, Aaronson SA.

PLoS Genet. 2013;9(8):e1003603. doi: 10.1371/journal.pgen.1003603. Epub 2013 Aug 15.

27.

A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis.

Kracikova M, Akiri G, George A, Sachidanandam R, Aaronson SA.

Cell Death Differ. 2013 Apr;20(4):576-88. doi: 10.1038/cdd.2012.155. Epub 2013 Jan 11.

28.

Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer.

Shapiro M, Akiri G, Chin C, Wisnivesky JP, Beasley MB, Weiser TS, Swanson SJ, Aaronson SA.

Ann Surg. 2013 Mar;257(3):548-54. doi: 10.1097/SLA.0b013e31826d81fd.

29.

Expression of the p53 target CDIP correlates with sensitivity to TNFα-induced apoptosis in cancer cells.

Brown-Endres L, Schoenfeld D, Tian F, Kim HG, Namba T, Muñoz-Fontela C, Mandinova A, Aaronson SA, Lee SW.

Cancer Res. 2012 May 1;72(9):2373-82. doi: 10.1158/0008-5472.CAN-11-3369.

30.

p53-mediated heterochromatin reorganization regulates its cell fate decisions.

Mungamuri SK, Benson EK, Wang S, Gu W, Lee SW, Aaronson SA.

Nat Struct Mol Biol. 2012 Apr 1;19(5):478-84, S1. doi: 10.1038/nsmb.2271.

31.

p53 serves as a host antiviral factor that enhances innate and adaptive immune responses to influenza A virus.

Muñoz-Fontela C, Pazos M, Delgado I, Murk W, Mungamuri SK, Lee SW, García-Sastre A, Moran TM, Aaronson SA.

J Immunol. 2011 Dec 15;187(12):6428-36. doi: 10.4049/jimmunol.1101459. Epub 2011 Nov 21.

32.

Differential effects on p53-mediated cell cycle arrest vs. apoptosis by p90.

Dai C, Tang Y, Jung SY, Qin J, Aaronson SA, Gu W.

Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):18937-42. doi: 10.1073/pnas.1110988108. Epub 2011 Nov 14.

33.

Acetylation is indispensable for p53 antiviral activity.

Muñoz-Fontela C, González D, Marcos-Villar L, Campagna M, Gallego P, González-Santamaría J, Herranz D, Gu W, Serrano M, Aaronson SA, Rivas C.

Cell Cycle. 2011 Nov 1;10(21):3701-5. doi: 10.4161/cc.10.21.17899. Epub 2011 Nov 1.

34.

High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A.

Vijayakumar S, Liu G, Rus IA, Yao S, Chen Y, Akiri G, Grumolato L, Aaronson SA.

Cancer Cell. 2011 May 17;19(5):601-12. doi: 10.1016/j.ccr.2011.03.010.

35.

DDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation.

Kim HG, Hwang SY, Aaronson SA, Mandinova A, Lee SW.

J Biol Chem. 2011 May 20;286(20):17672-81. doi: 10.1074/jbc.M111.236612. Epub 2011 Mar 13.

36.

Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors.

Grumolato L, Liu G, Mong P, Mudbhary R, Biswas R, Arroyave R, Vijayakumar S, Economides AN, Aaronson SA.

Genes Dev. 2010 Nov 15;24(22):2517-30. doi: 10.1101/gad.1957710.

37.

Diverse mechanisms of Wnt activation and effects of pathway inhibition on proliferation of human gastric carcinoma cells.

Asciutti S, Akiri G, Grumolato L, Vijayakumar S, Aaronson SA.

Oncogene. 2011 Feb 24;30(8):956-66. doi: 10.1038/onc.2010.475. Epub 2010 Nov 1.

38.

Abelson family kinases regulate Frizzled planar cell polarity signaling via Dsh phosphorylation.

Singh J, Yanfeng WA, Grumolato L, Aaronson SA, Mlodzik M.

Genes Dev. 2010 Oct 1;24(19):2157-68. doi: 10.1101/gad.1961010. Epub 2010 Sep 13.

39.

Role of progerin-induced telomere dysfunction in HGPS premature cellular senescence.

Benson EK, Lee SW, Aaronson SA.

J Cell Sci. 2010 Aug 1;123(Pt 15):2605-12. doi: 10.1242/jcs.067306. Epub 2010 Jul 6.

40.

Drosophila Abelson kinase mediates cell invasion and proliferation through two distinct MAPK pathways.

Singh J, Aaronson SA, Mlodzik M.

Oncogene. 2010 Jul 15;29(28):4033-45. doi: 10.1038/onc.2010.155. Epub 2010 May 10.

41.

GAMT joins the p53 network: branching into metabolism.

Ide T, Chu K, Aaronson SA, Lee SW.

Cell Cycle. 2010 May;9(9):1706-10. Epub 2010 May 10.

PMID:
20404548
42.

Protection of cells in physiological oxygen tensions against DNA damage-induced apoptosis.

Carrera S, de Verdier PJ, Khan Z, Zhao B, Mahale A, Bowman KJ, Zainol M, Jones GD, Lee SW, Aaronson SA, Macip S.

J Biol Chem. 2010 Apr 30;285(18):13658-65. doi: 10.1074/jbc.M109.062562. Epub 2010 Mar 12.

43.

Dual Role of p53 in Innate Antiviral Immunity.

Rivas C, Aaronson SA, Munoz-Fontela C.

Viruses. 2010 Jan;2(1):298-313. doi: 10.3390/v2010298. Epub 2010 Jan 22.

44.

GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress.

Ide T, Brown-Endres L, Chu K, Ongusaha PP, Ohtsuka T, El-Deiry WS, Aaronson SA, Lee SW.

Mol Cell. 2009 Nov 13;36(3):379-92. doi: 10.1016/j.molcel.2009.09.031. Retraction in: Mol Cell. 2013 Aug 22;51(4):552.

45.

Effects of p21 deletion in mouse models of premature aging.

Benson EK, Zhao B, Sassoon DA, Lee SW, Aaronson SA.

Cell Cycle. 2009 Jul 1;8(13):2002-4. Epub 2009 Jul 12.

46.

Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma.

Akiri G, Cherian MM, Vijayakumar S, Liu G, Bafico A, Aaronson SA.

Oncogene. 2009 May 28;28(21):2163-72. doi: 10.1038/onc.2009.82. Epub 2009 Apr 20.

47.

Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes.

Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Castedo M, Cidlowski JA, Ciechanover A, Cohen GM, De Laurenzi V, De Maria R, Deshmukh M, Dynlacht BD, El-Deiry WS, Flavell RA, Fulda S, Garrido C, Golstein P, Gougeon ML, Green DR, Gronemeyer H, Hajnóczky G, Hardwick JM, Hengartner MO, Ichijo H, Jäättelä M, Kepp O, Kimchi A, Klionsky DJ, Knight RA, Kornbluth S, Kumar S, Levine B, Lipton SA, Lugli E, Madeo F, Malomi W, Marine JC, Martin SJ, Medema JP, Mehlen P, Melino G, Moll UM, Morselli E, Nagata S, Nicholson DW, Nicotera P, Nuñez G, Oren M, Penninger J, Pervaiz S, Peter ME, Piacentini M, Prehn JH, Puthalakath H, Rabinovich GA, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Scorrano L, Simon HU, Steller H, Tschopp J, Tsujimoto Y, Vandenabeele P, Vitale I, Vousden KH, Youle RJ, Yuan J, Zhivotovsky B, Kroemer G.

Cell Death Differ. 2009 Aug;16(8):1093-107. doi: 10.1038/cdd.2009.44. Epub 2009 Apr 17. Review.

48.

Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells.

Liu G, Vijayakumar S, Grumolato L, Arroyave R, Qiao H, Akiri G, Aaronson SA.

J Cell Biol. 2009 Apr 6;185(1):67-75. doi: 10.1083/jcb.200810137.

49.

Cellular senescence and organismal ageing in the absence of p21(CIP1/WAF1) in ku80(-/-) mice.

Zhao B, Benson EK, Qiao R, Wang X, Kim S, Manfredi JJ, Lee SW, Aaronson SA.

EMBO Rep. 2009 Jan;10(1):71-8. doi: 10.1038/embor.2008.220. Epub 2008 Dec 12. Erratum in: EMBO Rep. 2011 Mar;12(3):283.

50.

Identification of ROCK1 as an upstream activator of the JIP-3 to JNK signaling axis in response to UVB damage.

Ongusaha PP, Qi HH, Raj L, Kim YB, Aaronson SA, Davis RJ, Shi Y, Liao JK, Lee SW.

Sci Signal. 2008 Nov 25;1(47):ra14. doi: 10.1126/scisignal.1161938.

Supplemental Content

Loading ...
Support Center